NASDAQ:AKBA - Akebia Therapeutics Stock Price, Forecast & News

Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."

Akebia Therapeutics Inc (NASDAQ:AKBA) announced its quarterly earnings data on Tuesday, November, 12th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by $0.09. The biopharmaceutical company had revenue of $91.98 million for the quarter, compared to analysts' expectations of $93.94 million. Akebia Therapeutics had a negative net margin of 75.39% and a negative return on equity of 32.74%. View Akebia Therapeutics' Earnings History.

Akebia Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 24th 2020. View Earnings Estimates for Akebia Therapeutics.

5 equities research analysts have issued twelve-month target prices for Akebia Therapeutics' shares. Their forecasts range from $9.00 to $17.00. On average, they expect Akebia Therapeutics' stock price to reach $13.80 in the next twelve months. This suggests a possible upside of 50.2% from the stock's current price. View Analyst Price Targets for Akebia Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akebia Therapeutics.

News stories about AKBA stock have been trending extremely negative on Tuesday, according to InfoTrie. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Akebia Therapeutics earned a news impact score of -5.0 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Akebia Therapeutics.

Akebia Therapeutics saw a decline in short interest during the month of January. As of January 31st, there was short interest totalling 9,340,000 shares, a decline of 5.1% from the January 15th total of 9,840,000 shares. Based on an average trading volume of 1,490,000 shares, the short-interest ratio is presently 6.3 days. Approximately 8.8% of the company's shares are short sold. View Akebia Therapeutics' Current Options Chain.

Some companies that are related to Akebia Therapeutics include Nektar Therapeutics (NKTR), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), HUTCHISON CHINA/S (HCM), Mirati Therapeutics (MRTX), Blueprint Medicines (BPMC), PTC Therapeutics (PTCT), Ultragenyx Pharmaceutical (RARE), SAGE Therapeutics (SAGE), Zai Lab (ZLAB), Emergent Biosolutions (EBS), Myokardia (MYOK), Allakos (ALLK), Axsome Therapeutics (AXSM) and Apellis Pharmaceuticals (APLS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Chesapeake Energy (CHK), Gilead Sciences (GILD), FireEye (FEYE), Energy Transfer LP Unit (ET), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), AT&T (T), Keryx Biopharmaceuticals (KERX) and AbbVie (ABBV).

Akebia Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Baupost Group LLC MA (16.45%), State Street Corp (2.89%), Point72 Asset Management L.P. (1.98%), Rice Hall James & Associates LLC (1.18%), Goldman Sachs Group Inc. (0.63%) and Charles Schwab Investment Management Inc. (0.61%). Company insiders that own Akebia Therapeutics stock include John P Butler, Steven C Gilman and Steven Keith Burke. View Institutional Ownership Trends for Akebia Therapeutics.

AKBA stock was sold by a variety of institutional investors in the last quarter, including Baupost Group LLC MA, State Street Corp, UBS Group AG, Old West Investment Management LLC, Rice Hall James & Associates LLC, Rafferty Asset Management LLC, Boston Partners and Massachusetts Financial Services Co. MA. View Insider Buying and Selling for Akebia Therapeutics.

AKBA stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Goldman Sachs Group Inc., Jacobs Levy Equity Management Inc., AQR Capital Management LLC, Russell Investments Group Ltd., Renaissance Technologies LLC, California Public Employees Retirement System and FMR LLC. Company insiders that have bought Akebia Therapeutics stock in the last two years include John P Butler, Steven C Gilman and Steven Keith Burke. View Insider Buying and Selling for Akebia Therapeutics.

Shares of AKBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AKBA stock can currently be purchased for approximately $9.19.

Akebia Therapeutics has a market capitalization of $1.09 billion and generates $207.74 million in revenue each year. The biopharmaceutical company earns $-143,590,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis. Akebia Therapeutics employs 324 workers across the globe.View Additional Information About Akebia Therapeutics.

The official website for Akebia Therapeutics is http://www.akebia.com/.

Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-2098 or via email at [email protected]